Market Place
Sourcing Support
Evgen completes three cohorts for SFX-01
25 Jan 2023 //
PHARMATIMES
Evgen to investigate new SFX-01 tablet formulation
16 Nov 2022 //
PHARMATIMES
Regulatory approval received for Evgen’s SFX-01 study
29 Sep 2022 //
PHARMATIMES
Evgen Pharma and University of Michigan to study colorectal cancer asset
14 Jun 2022 //
PHARMACEUTICAL-TECHNOLOGY
Publication of data on SFX-01 in glioblastoma
10 Nov 2021 //
SHARESMAGAZINE
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells
20 Sep 2021 //
INVESTEGATE
Evgen Pharma’s SFX-01 granted orphan drug designation for malignant glioma
01 Sep 2021 //
PROACTIVEINVESTORS
Progress with Glioma/Glioblastoma programme
14 Jun 2021 //
FT
Progress on metastatic breast cancer programme
14 Jun 2021 //
SHARECAST
Evgen Pharma recruits over 100 patients into COVID-19 trial
17 Feb 2021 //
PHARMATIMES
Placing and Open Offer to raise up to £11 million
02 Feb 2021 //
INVESTGATE
Recruitment of first patient in STAR trial
23 Nov 2020 //
INVESTEGATE
Juvenescence Announces Licensing Agreement with Evgen Pharma plc
15 Sep 2020 //
BUSINESSNEWS WIRE
Evgen`s SFX-01 selected for COVID-19 trial
17 Jun 2020 //
PHARMATIMES
Evgen`s SFX-01 selected for COVID-19 trial
16 Jun 2020 //
PHARMATIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.